ATE304866T1 - Chelatorkonjugate mit verbesserten eigenschaften - Google Patents

Chelatorkonjugate mit verbesserten eigenschaften

Info

Publication number
ATE304866T1
ATE304866T1 AT02745600T AT02745600T ATE304866T1 AT E304866 T1 ATE304866 T1 AT E304866T1 AT 02745600 T AT02745600 T AT 02745600T AT 02745600 T AT02745600 T AT 02745600T AT E304866 T1 ATE304866 T1 AT E304866T1
Authority
AT
Austria
Prior art keywords
improved properties
chelator conjugates
radiometal
conjugates
chelator
Prior art date
Application number
AT02745600T
Other languages
English (en)
Inventor
Colin Mill Archer
Harry John Wadsworth
Torgrim Amersham Engell
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Application granted granted Critical
Publication of ATE304866T1 publication Critical patent/ATE304866T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT02745600T 2001-07-10 2002-07-10 Chelatorkonjugate mit verbesserten eigenschaften ATE304866T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates
PCT/GB2002/003168 WO2003006070A2 (en) 2001-07-10 2002-07-10 Improved chelator conjugates

Publications (1)

Publication Number Publication Date
ATE304866T1 true ATE304866T1 (de) 2005-10-15

Family

ID=9918227

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745600T ATE304866T1 (de) 2001-07-10 2002-07-10 Chelatorkonjugate mit verbesserten eigenschaften

Country Status (20)

Country Link
US (2) US7597875B2 (de)
EP (1) EP1404377B1 (de)
JP (1) JP5015409B2 (de)
KR (1) KR100892009B1 (de)
CN (4) CN101537190A (de)
AT (1) ATE304866T1 (de)
AU (1) AU2002317317B2 (de)
BR (1) BR0210965A (de)
CA (1) CA2450690C (de)
DE (1) DE60206272T2 (de)
DK (1) DK1404377T3 (de)
ES (1) ES2250671T3 (de)
GB (1) GB0116815D0 (de)
HU (1) HU228850B1 (de)
IL (1) IL159388A0 (de)
MX (1) MXPA04000210A (de)
NO (1) NO334093B1 (de)
RU (1) RU2298012C2 (de)
WO (1) WO2003006070A2 (de)
ZA (1) ZA200400143B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002239655A1 (en) 2001-01-05 2002-07-16 Duke University Contrast enhancement agent for magnetic resonance imaging
ES2719088T3 (es) * 2001-07-10 2019-07-08 Ge Healthcare Ltd Compuestos con base peptídica para localizar receptores de integrina
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
JP2007510643A (ja) * 2003-11-06 2007-04-26 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
EP1699494A2 (de) * 2003-11-24 2006-09-13 GE Healthcare AS Kontrastmittel-darstellung angiotensin-ii-rezeptoren
EP1729823B1 (de) * 2004-03-04 2009-11-04 GE Healthcare AS Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie
BRPI0518328A2 (pt) 2004-11-22 2008-11-11 Ge Healthcare As agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
WO2006131803A2 (en) * 2005-06-08 2006-12-14 Ge Healthcare Limited Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled esters and acids by sensitized photo-induced free radical carbonylation
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
WO2007094683A1 (en) 2006-02-15 2007-08-23 Ge Healthcare As Contrast agents
US7943117B2 (en) * 2006-06-08 2011-05-17 Atomic Energy Council—Institute of Nuclear Research Method for testing radiochemical purity of Tc-99m-TRODAT-1
MX2009006028A (es) * 2006-12-11 2009-06-17 Ge Healthcare As Compuestos basados en peptido radiomarcado y usos de los mismos.
ES2712881T3 (es) 2008-12-02 2019-05-16 Univ Melbourne Conjugados macrocíclicos que contienen nitrógeno como radiofármacos
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
EP2598175B1 (de) * 2010-07-27 2020-05-20 Serac Healthcare Limited Radiopharmazeutische zusammensetzungen
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
US20130195756A1 (en) 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
WO2014126902A1 (en) * 2013-02-15 2014-08-21 Thomas Jefferson University Kit for tumor imaging
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
ES2824674T3 (es) 2014-03-19 2021-05-13 Univ Zuerich Agentes quelantes bifuncionales multidentados para la complejación de radionúclidos en el diagnóstico y la terapia
CN112840025A (zh) * 2018-05-08 2021-05-25 迈阿密大学 用于将治疗性核酸递送到组织的材料方法
EP3793619A4 (de) 2018-05-16 2022-01-12 Emory University Styrylbenzothiazolderivate und ihre verwendung in der bilderzeugung
CN111548275A (zh) * 2020-05-27 2020-08-18 龙曦宁(上海)医药科技有限公司 一种2-(氨基甲基)-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588978A (en) * 1977-07-19 1981-05-07 Ici Ltd Coating processes
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
US5997843A (en) * 1993-08-04 1999-12-07 Amersham International Plc Radiometal complexes that localise in hypoxic tissue
DE69501981T2 (de) * 1994-01-12 1998-12-10 Bracco International B.V., Amsterdam Liganden und deren metallkomplexe
CA2179990A1 (en) * 1994-01-12 1995-07-20 Gary Robert Bower Biological targeting agents
DE69937996T2 (de) 1998-05-15 2009-01-02 Ge Healthcare Ltd., Little Chalfont Markierte glutamin- und lysinanaloge
US6783711B2 (en) * 2000-05-23 2004-08-31 Ge Osmonics, Inc. Process for preparing a sulfonamide polymer matrix
JP4009198B2 (ja) * 2001-03-08 2007-11-14 松下電器産業株式会社 インクジェット記録用インク、該インクの製造方法、並びに該インクを備えたインクカートリッジ及び記録装置

Also Published As

Publication number Publication date
KR100892009B1 (ko) 2009-04-07
JP2005500325A (ja) 2005-01-06
NO20035597L (no) 2004-03-03
GB0116815D0 (en) 2001-08-29
US8852550B2 (en) 2014-10-07
HK1064585A1 (en) 2005-02-04
WO2003006070A3 (en) 2003-08-21
DE60206272D1 (de) 2005-10-27
AU2002317317B2 (en) 2005-11-17
CN101607913B (zh) 2012-07-04
DE60206272T2 (de) 2006-07-13
KR20040017287A (ko) 2004-02-26
IL159388A0 (en) 2004-06-01
CN101607913A (zh) 2009-12-23
US20040258619A1 (en) 2004-12-23
ZA200400143B (en) 2004-12-29
CN101538313A (zh) 2009-09-23
HU228850B1 (en) 2013-06-28
CN1527727A (zh) 2004-09-08
RU2298012C2 (ru) 2007-04-27
BR0210965A (pt) 2004-06-08
US20100040542A1 (en) 2010-02-18
CA2450690C (en) 2009-03-24
NO20035597D0 (no) 2003-12-16
HUP0401265A2 (hu) 2004-09-28
CN101537190A (zh) 2009-09-23
CA2450690A1 (en) 2003-01-23
EP1404377A2 (de) 2004-04-07
NO334093B1 (no) 2013-12-09
US7597875B2 (en) 2009-10-06
ES2250671T3 (es) 2006-04-16
MXPA04000210A (es) 2004-07-23
DK1404377T3 (da) 2006-01-30
WO2003006070A2 (en) 2003-01-23
HUP0401265A3 (en) 2005-11-28
JP5015409B2 (ja) 2012-08-29
RU2003137592A (ru) 2005-05-20
CN100509061C (zh) 2009-07-08
EP1404377B1 (de) 2005-09-21

Similar Documents

Publication Publication Date Title
DE60206272D1 (de) Chelatorkonjugate mit verbesserten eigenschaften
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
ECSP034600A (es) Compuestos de lactama
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
DE60213276D1 (de) 1,2,4-thiadiazoliumverbindungen als melanocortinrezeptor-modulatoren
BR0216099B1 (pt) "conjunto de desgaste".
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
IL181529A (en) A method for radiofluorination, a compound containing radioactive fluorine and its use in the preparation of a radioactive drug
TR200003389T2 (tr) 2-(2-klorofenil)-3,4-dihidro-2H-pirol türevleri.
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
TR199901017A2 (xx) B�cek ilac� terkibi.
DE10108995A1 (de) Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ID27733A (id) Metoksiminofenilasetamida
ITTO20020747A1 (it) Composizione.
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
ITTO20020745A1 (it) Composizione.
FR2845696B1 (fr) Non-tisses microfibreux, complexes les incorporant, preparations
TR200102093T2 (tr) Organ koruyucu çözeltiler
UA50172A (uk) Засіб для лікування мігрені
UA115859C2 (uk) Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить
MY143246A (en) Triazole substituted aminobensophenone compounds
ITTO20020746A1 (it) Composizione.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1404377

Country of ref document: EP